SunTrust Robinson Humphrey downgraded Tetraphase Pharmaceuticals (NASDAQ: TTPH) from Buy to Neutral with a price target of $12.00 (from $54.00).

For an analyst ratings summary and ratings history on Tetraphase Pharmaceuticals click here. For more ratings news on Tetraphase Pharmaceuticals click here.

Shares of Tetraphase Pharmaceuticals closed at $44.78 yesterday.

Analyst PT Change Downgrades

Nomura Securities Downgrades Tetraphase Pharmaceuticals (TTPH) to NeutralSeptember 9, 2015 8:06 AM Stifel Downgrades Tetraphase Pharmaceuticals (TTPH) to HoldSeptember 9, 2015 8:01 AM Guggenheim Cuts Price Target on Tetraphase Pharma (TTPH) Following Disappointing cUTI Data. September 9, 2015 7:57 AM Needham & Company Downgrades Tetraphase Pharmaceuticals (TTPH) to HoldSeptember 9, 2015 7:40 AM Brean Capital Downgrades Tetraphase Pharmaceuticals (TTPH) to HoldSeptember 9, 2015 7:32 AM Baird Downgrades Tetraphase Pharmaceuticals (TTPH) to NeutralSeptember 9, 2015 7:30 AM Wedbush Downgrades Tetraphase Pharmaceuticals (TTPH) to NeutralSeptember 9, 2015 7:20 AM UPDATE: Cantor Fitzgerald Downgrades Tetraphase Pharmaceuticals (TTPH) to HoldSeptember 9, 2015 7:11 AM Tetraphase Pharma's (TTPH) IGNITE2 Phase 3 Missed Primary Endpoint in cUTISeptember 8, 2015 4:02 PM Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTISeptember 8, 2015 4:01 PM